|
Icosapent Ethyl Capsules (USRLD: Vascepa Capsules) are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Icosapent Ethyl Capsules, 0.5 g and 1 g had annual sales of $1,316 million in the United States (IQVIA MAT Feb. 2023).
The group now has 365 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is engaged in an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes active pharmaceutical ingredients [API] and human formulations.
The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q4 FY23 over Q4 FY22.
The scrip rose 0.73% to Rs 517.30 on 21 April 2023.
|